- Home
- CCII vs PBYI Comparison
CCII vs PBYI Comparison
Compare CCII & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$7.51
Company Overview
Basic Information| Metric | CCII | PBYI |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.3M | 343.9M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | CCII | PBYI |
|---|---|---|
| Price | $10.25 | $7.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.4K | ★ 242.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.07 | $2.69 |
| 52 Week High | $10.47 | $7.68 |
Technical Indicators
Market Signals| Indicator | CCII | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 71.09 |
| Support Level | $10.20 | $6.21 |
| Resistance Level | $10.30 | N/A |
| Average True Range (ATR) | 0.03 | 0.29 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 42.86 | 100.00 |
Price Performance
Historical Comparison CCII
PBYI
About CCII Cohen Circle Acquisition Corp. II Class A Ordinary Shares
Cohen Circle Acquisition Corp II is a blank check company.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.